ClinicalTrials.gg
CompletedNCT03011372Updated Nov 18, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

A Phase 2 interventional study of Pemigatinib in MPN (Myeloproliferative Neoplasms), sponsored by Incyte Corporation. Completed at 33 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Myeloproliferative Disorders by Incyte Corporation — 3 open to participants now, 7 under way, none of them phase 3. Myeloproliferative Disorders · Incyte Corporation.

Enrollment
18th of 23
47 · median 97
Started
2017
with 2 others
Phase 2
10 of 25
none open now
Registered
13th of 25
by date

Among the 25 studies in Myeloproliferative Disorders by Incyte Corporation, this one is the 18th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 in phase 2, and was the 13th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

3 of the 25 studies in Myeloproliferative Disorders by Incyte Corporation are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 88 Myeloproliferative Disorders studies recruiting now, 64 (73%) set no upper age limit and 18 (20%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Myeloproliferative Disorders by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.

03

Conditions studied

  • MPN (Myeloproliferative Neoplasms)

Keywords

  • Myeloid neoplasm
  • fibroblast growth factor receptor inhibitor
  • FGFR1 rearrangement
  • 8p11
  • eosinophilia
  • eosinophilic syndrome
  • Lymphoid neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation, based on standard diagnostic cytogenetic evaluation performed locally, before signing for this study.
  • Eligible subjects must:

    • Have after stem cell transplantation or after other disease modifying therapy, OR
    • Not be current candidates for stem cell transplantation or other disease modifying therapies.
  • Note: All relapsed/refractory subjects must have evidence of either cytogenetic or hematological disease and have no evidence of residual toxicity (eg, requiring treatment).
  • ≥ 12 weeks.
  • (ECOG) performance status 0 to 2.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a selective FGFR inhibitor.
  • History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, except calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.
  • Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis, as confirmed by ophthalmologic examination.
  • Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Pemigatinib

    Drug: Pemigatinib

Interventions

  • Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy. Participants will receive either the intermittent dose (as written) or continuous dosing.

    Also known as: INCB054828

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

    CR was defined as the presence of all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent or equal to "mild reticulin fibrosis" (Grade 1 or less fibrosis); (3) peripheral blood: white blood cells (WBC) ≤10 x 10\^9 cells/Liter (L); hemoglobin (Hgb) ≥11 grams per deciliter (g/dL); platelets ≥100 x 10\^9/L and ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts = 0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present before therapy (e.g., lymphadenopathy), including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted given subjectivity of assignment of dysplasia. Response criteria by investigator assessment were the same for chronic phase (CP) and blast phase (BP).

    Time frame: up to 2513 days (120 21-day treatment cycles)

Secondary outcomes

  1. Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

    CR=all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent/equal to "mild reticulin fibrosis"; (3) WBC ≤10 x 10\^9 cells/L; Hgb ≥11 g/dL; platelets ≥100 x 10\^9/L, ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts=0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present pre-therapy, including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted. PR=all of the following improvements: (1) reduction of bone marrow blasts/blast equivalents by 50%, but remaining \>5% of cellularity (except in cases with ≤5% bone marrow blasts at baseline); (2) normalization of peripheral blood indices per CR Criterion 3; (3) extra medullary disease response of CMR/CR or PMR/PR.

    Time frame: up to 2513 days (120 21-day treatment cycles)

  2. Percentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation

    CCyR was defined as 0% 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or fluorescence in situ hybridization (FISH). Loss of cytogenetic burden of disease (via FISH or classic karyotyping) was required to reach CCyR.

    Time frame: up to 2513 days (120 21-day treatment cycles)

  3. Percentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation

    PCyR was defined as the decrease from baseline of 50% or more 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or FISH.

    Time frame: up to 2513 days (120 21-day treatment cycles)

  4. Percentage of Participants Who Achieved a PCyR as Assessed by CRC Assessment

    In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

    Time frame: up to 2513 days (120 21-day treatment cycles)

  5. Duration of Complete Response

    Duration of complete response was defined as the time from the first assessment of complete response to the earlier of the date of first worsening assessment after complete response or death due to any cause

    Time frame: up to 2513 days (120 21-day treatment cycles)

  6. Duration of Response

    Duration of response was defined as the time from the first assessment of complete response or partial response to the earlier of the date of first worsening assessment after response or death due to any cause.

    Time frame: up to 2513 days (120 21-day treatment cycles)

  7. Progression-free Survival (PFS)

    PFS was defined as the time from the first date of taking study drug until the date of disease progression or until death due to any cause, whichever was earlier. Disease progression was defined as the combination of 2 major criteria, 1 major and 2 minor criteria, or 3 minor criteria from the following lists. Major criteria: (1) increase in blast count; (2) evidence of cytogenetic evolution (re-appearance of a previously present or appearance of a new cytogenetic abnormality, or increase in cytogenetic burden of disease); (3) new or worsening extramedullary disease (worsening splenomegaly or extramedullary disease outside of the spleen). Minor criteria: (1) transfusion dependence; (2) significant loss of maximal response on cytopenias ≥50% decrement from maximum remission/response in granulocytes or platelets; (3) reduction in Hgb by ≥1.5g/dL from best response or from baseline as noted on complete blood count; (4) evidence of clonal evolution (molecular).

    Time frame: up to 2513 days (120 21-day treatment cycles)

  8. Overall Survival

    Overall survival was defined as as the time from the first day of taking study drug until death due to any cause

    Time frame: up to 2513 days (120 21-day treatment cycles)

  9. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug.

    Time frame: up to 2543 days

  10. Number of Participants With Any ≥Grade 3 TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

    Time frame: up to 2543 days

Other outcomes

  1. Percentage of Participants Who Achieved CR as Determined by Central Review Committee (CRC) Assessment

    In addition, responses were assessed by CRC based on Myeloid/Lymphoid Neoplasm International Working Group (MLN IWG) response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

    Time frame: up to 2513 days (120 21-day treatment cycles)

  2. Percentage of Participants Who Achieved a Best Overall Response of CR or PR as Determined by CRC Assessment

    In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

    Time frame: up to 2513 days (120 21-day treatment cycles)

  3. Percentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment

    In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

    Time frame: up to 2513 days (120 21-day treatment cycles)

07

Results

Posted Nov 18, 2025

Participant flow

Participant flow — Overall Study
MilestonePemigatinib 13.5 mg
Started47
Completed0
Not completed47
Withdrew: Death16
Withdrew: Lost to follow-up2
Withdrew: Sponsor decision17
Withdrew: Withdrawal by subject7
Withdrew: Moved to commercial supply of investigational drug2
Withdrew: Received first dose of chemotherapy for stem cell transplant1
Withdrew: Sponsor's decision2

Outcome measures

PrimaryPercentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

CR was defined as the presence of all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent or equal to "mild reticulin fibrosis" (Grade 1 or less fibrosis); (3) peripheral blood: white blood cells (WBC) ≤10 x 10\^9 cells/Liter (L); hemoglobin (Hgb) ≥11 grams per deciliter (g/dL); platelets ≥100 x 10\^9/L and ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts = 0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present before therapy (e.g., lymphadenopathy), including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted given subjectivity of assignment of dysplasia. Response criteria by investigator assessment were the same for chronic phase (CP) and blast phase (BP).

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement68.9 (53.35 to 81.83)
Other pre-specifiedPercentage of Participants Who Achieved CR as Determined by Central Review Committee (CRC) Assessment

In addition, responses were assessed by CRC based on Myeloid/Lymphoid Neoplasm International Working Group (MLN IWG) response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved CR as Determined by Central Review Committee (CRC) Assessment
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved CR as Determined by Central Review Committee (CRC) Assessment68.9 (53.35 to 81.83)
SecondaryPercentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

CR=all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent/equal to "mild reticulin fibrosis"; (3) WBC ≤10 x 10\^9 cells/L; Hgb ≥11 g/dL; platelets ≥100 x 10\^9/L, ≤450 x 10\^9/L; neutrophils ≥1.0 x 10\^9/L; blasts=0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\^9/L; eosinophils ≤0.5 x 10\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present pre-therapy, including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted. PR=all of the following improvements: (1) reduction of bone marrow blasts/blast equivalents by 50%, but remaining \>5% of cellularity (except in cases with ≤5% bone marrow blasts at baseline); (2) normalization of peripheral blood indices per CR Criterion 3; (3) extra medullary disease response of CMR/CR or PMR/PR.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement77.8 (62.91 to 88.80)
Other pre-specifiedPercentage of Participants Who Achieved a Best Overall Response of CR or PR as Determined by CRC Assessment

In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Best Overall Response of CR or PR as Determined by CRC Assessment
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved a Best Overall Response of CR or PR as Determined by CRC Assessment75.6 (60.46 to 87.12)
SecondaryPercentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation

CCyR was defined as 0% 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or fluorescence in situ hybridization (FISH). Loss of cytogenetic burden of disease (via FISH or classic karyotyping) was required to reach CCyR.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved a Complete Cytogenetic Response (CCyR) as Assessed by Local Analysis and Investigator Evaluation73.3 (58.06 to 85.40)
Other pre-specifiedPercentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment

In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment73.3 (58.06 to 85.40)
SecondaryPercentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation

PCyR was defined as the decrease from baseline of 50% or more 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or FISH.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation8.9 (2.48 to 21.22)
SecondaryPercentage of Participants Who Achieved a PCyR as Assessed by CRC Assessment

In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PCyR as Assessed by CRC Assessment
percentage of participantsPemigatinib 13.5 mg
Percentage of Participants Who Achieved a PCyR as Assessed by CRC Assessment15.6 (6.49 to 29.46)
SecondaryDuration of Complete Response

Duration of complete response was defined as the time from the first assessment of complete response to the earlier of the date of first worsening assessment after complete response or death due to any cause

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Median · months
Duration of Complete Response
monthsPemigatinib 13.5 mg
Investigator assessment53.29 (12.22 to NA)
CRC assessmentNA (27.86 to NA)
SecondaryDuration of Response

Duration of response was defined as the time from the first assessment of complete response or partial response to the earlier of the date of first worsening assessment after response or death due to any cause.

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Median · months
Duration of Response
monthsPemigatinib 13.5 mg
Investigator assessment53.29 (15.51 to NA)
CRC assessmentNA (27.86 to NA)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the first date of taking study drug until the date of disease progression or until death due to any cause, whichever was earlier. Disease progression was defined as the combination of 2 major criteria, 1 major and 2 minor criteria, or 3 minor criteria from the following lists. Major criteria: (1) increase in blast count; (2) evidence of cytogenetic evolution (re-appearance of a previously present or appearance of a new cytogenetic abnormality, or increase in cytogenetic burden of disease); (3) new or worsening extramedullary disease (worsening splenomegaly or extramedullary disease outside of the spleen). Minor criteria: (1) transfusion dependence; (2) significant loss of maximal response on cytopenias ≥50% decrement from maximum remission/response in granulocytes or platelets; (3) reduction in Hgb by ≥1.5g/dL from best response or from baseline as noted on complete blood count; (4) evidence of clonal evolution (molecular).

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPemigatinib 13.5 mg
Investigator assessment73.89 (54.74 to NA)
CRC assessment73.89 (29.17 to NA)
SecondaryOverall Survival

Overall survival was defined as as the time from the first day of taking study drug until death due to any cause

Time frame:
up to 2513 days (120 21-day treatment cycles)
Reported as:
Median · months
Overall Survival
monthsPemigatinib 13.5 mg
Overall SurvivalNA (54.74 to NA)
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug.

Time frame:
up to 2543 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPemigatinib 13.5 mg
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)47
SecondaryNumber of Participants With Any ≥Grade 3 TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grades 1 through 4. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated.

Time frame:
up to 2543 days
Reported as:
Count of participants · Participants
Number of Participants With Any ≥Grade 3 TEAE
ParticipantsPemigatinib 13.5 mg
Number of Participants With Any ≥Grade 3 TEAE39

Adverse events

Collected over up to 2730 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemigatinib 13.5 mg16/47 (34%)27/47 (57.4%)46/47 (97.9%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventPemigatinib 13.5 mg
Acute kidney injuryRenal and urinary disorders4/47
Angina pectorisCardiac disorders2/47
Atrioventricular block completeCardiac disorders2/47
Myocardial infarctionCardiac disorders2/47
PneumoniaInfections and infestations2/47
SyncopeNervous system disorders2/47
Urinary tract infectionInfections and infestations2/47
AlopeciaSkin and subcutaneous tissue disorders1/47
Aortic stenosisVascular disorders1/47
Atrial flutterCardiac disorders1/47
Most frequent other events
Showing 10 of 136
Most frequent other events
EventPemigatinib 13.5 mg
HyperphosphataemiaMetabolism and nutrition disorders35/47
DiarrhoeaGastrointestinal disorders29/47
AlopeciaSkin and subcutaneous tissue disorders26/47
StomatitisGastrointestinal disorders21/47
ConstipationGastrointestinal disorders20/47
Dry eyeEye disorders20/47
Dry mouthGastrointestinal disorders19/47
NauseaGastrointestinal disorders17/47
Abdominal painGastrointestinal disorders16/47
AnaemiaBlood and lymphatic system disorders16/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pemigatinib 13.5 mg
Mean58.3 ± 13.25
Sex: Female, Male
Sex: Female, Male(Participants)Pemigatinib 13.5 mg
Female25
Male22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pemigatinib 13.5 mg
White30
Black or African American4
Asian4
Missing5
Not Provided2
White/Caucasian and American-Indian Alaska Native1
African1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pemigatinib 13.5 mg
Hispanic or Latino1
Not Hispanic or Latino33
Not Reported8
Unknown1
Captured as "Other" in Database4
08

Study locations

33 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • Emory University - Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Weill Cornell Medical Centers
    New York, New York 10021, United States
  • Md Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz
    Linz, 04010, Austria
  • Medical University of Vienna
    Vienna, 01090, Austria
  • Iii Med. Abteilung For Hematologie and Onkologie Hanuscfhkrankenhaus
    Vienna, 01140, Austria
  • Universitair Ziekenhuis (Uz) Leuven
    Leuven, 03000, Belgium
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G 2M9, Canada
  • Centre Leon Berard
    Lyon, 69373, France
  • Chu de Nice - Hospital L Archet
    Nice, 06202, France
  • Hospital Saint Louis
    Paris, 75475, France
  • Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
    Toulouse, 31059, France
  • University Medical Center Rwth Aachen
    Aachen, D-52074, Germany
  • Universitatsklinikum Halle (Saale)
    Halle, 06120, Germany
  • Universitatsklinikum Jena
    Jena, 07740, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • University Hospital Mannheim
    Mannheim, 68167, Germany
  • Johannes Wesling Klinikum Minden
    Minden, 32429, Germany
  • Ospedale Papa Giovanni Xxiii
    Bergamo, 24127, Italy
  • Azienda Ospedaliero-Universitaria Careggi (Aouc)
    Florence, 50134, Italy
  • Kindai University Hospital
    Osaka, 589-8511, Japan
  • Ntt Medical Center Tokyo
    Tokyo, 141-8625, Japan
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Inselspital - Universitaetsspital Bern
    Bern, 03010, Switzerland
  • Universitatsspital Zurich
    Zurich, 08091, Switzerland
  • Guys and St Thomas Nhs Foundation Trust
    London, SE1 9RT, United Kingdom
  • Oxford University Hospitals Nhs Foundation Trust
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Al-Bazaz M, Forstreuter A, Hammada I, Hille J, Wagner JN, Reinert J, Wehrhahn J, Bokemeyer C, Fiedler W. Acute Lymphoblastic Leukemia Characterized by Rare BCR::FGFR1 Translocation: A Case Report With Literature Review. Case Rep Hematol. 2025 Oct 23;2025:8892036. doi: 10.1155/crh/8892036. eCollection 2025. PubMed 41180818 ↗
  • Verstovsek S, Kiladjian JJ, Vannucchi AM, Patel JL, Rambaldi A, Shomali WE, Oh ST, Usuki K, Harrison CN, Ritchie EK, Akard LP, Hernandez-Boluda JC, Huguet F, Colucci P, Zhen H, Oliveira N, Gilmartin A, Langford C, George TI, Reiter A, Gotlib J. Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement. NEJM Evid. 2025 Sep;4(9):EVIDoa2500017. doi: 10.1056/EVIDoa2500017. Epub 2025 Aug 26. PubMed 40856555 ↗
  • Subbiah V, Burris HA 3rd, Kurzrock R. Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 2024 Jan;130(2):186-200. doi: 10.1002/cncr.35085. Epub 2023 Nov 7. PubMed 37934000 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Oct 2024, 90 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 87 phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 111. This study's 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2017
First posted
Jan 5, 2017
StartActual
Apr 25, 2017
Primary completionActual
Oct 30, 2024
CompletionActual
Oct 30, 2024
Results first posted
Nov 18, 2025
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03011372
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jan 5, 2017
Start date
Apr 25, 2017
Primary completion
Oct 30, 2024
Completion
Oct 30, 2024
Results posted
Nov 18, 2025
Last update
Nov 18, 2025

Study contacts

Philomena Collucci, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion